Our Management Team is One of the Most Experienced
in the Biotech Industry

Edward Lanphier, the founder of Sangamo BioSciences, Inc., has served as President, Chief Executive Officer and as a member of the Board of Directors since Sangamo's inception in 1995. Mr. Lanphier has approximately twenty-five years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporation, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, he was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, he served as Vice President of Corporate Development at Biotherapeutics, Inc. From 1984 to 1986 Mr. Lanphier served as Vice President of Corporate Development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute. Mr. Lanphier holds a B.A. in biochemistry from Knox College.

David G. Ichikawa has served as Senior Vice President, Business Development since December 2004. Prior to joining Sangamo, Mr. Ichikawa was most recently Chief Business Officer for Sagres Discovery, where he was responsible for corporate strategy and business development activities. While at Sagres he negotiated a major collaboration with Boehringer Ingelheim, the strategic acquisition of MemRx Corporation and played a critical role in the acquisition of Sagres by Chiron Corporation. Prior to Sagres Discovery, David held several positions with Chiron Corporation including Vice President, R&D Business Development and Finance. Mr. Ichikawa earned his M.B.A. degree from the University of California at Berkeley and a B.S. degree from the University of California at Davis.

Dale Ando, M.D. has served as Vice President, Therapeutic Development and Chief Medical Officer since August 2004. Dr. Ando has held senior positions in therapeutic product development in several biotechnology companies most recently as Vice President, Clinical Research at Cell Genesys, Inc. While at Cell Genesys, Dr. Ando directed the development of Phase I-III GVAX programs, oncolytic virus programs and Phase I/II trials of chimaeric T-cell receptor products in HIV and cancer. Prior to joining Cell Genesys in 1997, Dr. Ando spent six years at Chiron Corporation as director of clinical gene therapy and three years at Cetus Corporation. From 1997 to 2001 Dr. Ando served as a member of the Recombinant DNA Advisory Committee (RAC) and the Adenoviral Safety Committee for the National Institutes of Health (NIH). Dr. Ando began his career as a faculty member at UCLA Medical School in the Division of Rheumatology. He received his M.D. and Internal Medicine training at the University of Michigan and a B.S. in Chemistry from Stanford University. Dr. Ando is board certified in internal medicine and is a subspecialist in Rheumatology.

Ely Benaim, M.D. has served as Vice President, Clinical Affairs since April 2007. Dr. Benaim has twenty years of experience in the medical field including ten years of clinical research experience in academia, government and the biotechnology and pharmaceutical industries. He most recently served as Global Development Leader, Global Clinical Development at Amgen, Inc. While at Amgen, Dr. Benaim oversaw the clinical development of multiple of oncology therapeutic drug candidates. Prior to joining Amgen in 2005, Dr. Benaim served as Global Senior Director, Oncology Clinical Development at Salmedix Inc. (now Cephalon, Inc.) where he led the development of TREANDA(R) (Bendamustine HCl) to a Phase 3 pivotal trial for lymphoma. Dr. Benaim received his M.D. from the Universidad Central de Venezuela, Caracas and completed his pediatric residency training at the University of South Florida. He completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude's Children's Research Hospital, Memphis, Tennessee. From 1997 to 2004, he was Assistant Professor in the Department of Pediatrics at the University of Tennessee and an Assistant Member to the Department of Hematology/Oncology. As a member of the Transplantation and Gene Therapy program he published several manuscripts on the areas of stem cell transplantation, immunology and gene therapy.

Philip D. Gregory, D. Phil. has served as Vice President, Research since October, 2005. He joined Sangamo in December 2000 as a Scientist, became a Team Leader in October, 2001and Senior Director, Research in July 2003. Prior to joining the company, Dr. Gregory was at the University of Munich, Germany, where he studied the role of chromatin structure in gene regulation and published extensively in this field. Dr. Gregory earned a D. Phil. In Biochemistry from the University of Oxford and holds a B.Sc. in microbiology from the University of Sheffield.

Ed Rebar, Ph.D. has served as Vice President, Technology since December 2007. He joined Sangamo in August 1998 as a Scientist, became a Team Leader in October 2001 and Senior Director, Technology in November 2003. Prior to joining Sangamo, he was a post-doctoral fellow at University of California, Berkeley. Dr. Rebar earned a Ph.D. from the Massachusetts Institute of Technology, where he developed phage display methods for engineering zinc fingers with novel DNA-binding specificities. Dr. Rebar has authored numerous publications and patents relating to the design and application of zinc finger proteins. He holds a B.S. in Biochemistry from Rutgers University

Eric Rhodes has served as Vice President of Business Development and Alliance Management since October, 2007 and joined the Company in July 1998 as Senior Director of Commercial Development. Mr. Rhodes has primary responsibility for the management of the company’s Enabling Technology businesses including small molecule discovery, protein production and functional genomics. Before joining Sangamo, he served in a variety of scientific and business development roles at Incyte Pharmaceuticals, a genomic database and data management software company. While there, Mr. Rhodes served on a team responsible for the expansion of Incyte’s high throughput sequencing capabilities. He subsequently worked in the business development group where his primary focus was the evaluation and acquisition of new technologies. Previously, Mr.Rhodes directed the molecular biology group at Anergen, Inc., a biotechnology company focused on developing new drugs to treat autoimmune diseases. He also worked for BioGrowth, Inc. and Triton BioSciences. Mr. Rhodes holds a B.S. in microbiology and immunology from the University of California, Berkeley.

Greg Zante, CPA, has served as Vice President, Finance and Administration since September 2006. He joined Sangamo as Senior Director, Finance and Administration in August 2003. Prior to joining Sangamo, Mr. Zante was Director, Finance and Administration of Calyx Therapeutics, Inc. a privately held pharmaceutical discovery and development company, from December 2001. From October 1993 until December 2001, Mr. Zante held senior financial managerial positions in several companies including Matrix Pharmaceuticals, Inc. He was employed by Ernst and Young, LLP as a Senior Staff Accountant from October 1993 until November 1995. Mr. Zante holds a B.A. in business-economics and managerial accounting from UCLA and is a Certified Public Accountant in the state of California.

Board of Directors

Edward Lanphier, the founder of Sangamo BioSciences, Inc., has served as President, Chief Executive Officer and as a member of the Board of Directors since Sangamo's inception in 1995. Mr. Lanphier has approximately twenty-five years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporation, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, he was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, he served as Vice President of Corporate Development at Biotherapeutics, Inc. From 1984 to 1986 Mr. Lanphier served as Vice President of Corporate Development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute. Mr. Lanphier holds a B.A. in biochemistry from Knox College.

William G. Gerber, M.D. has served as a member of our Board of Directors since June 1997. Dr. Gerber is currently a partner at Bay City Capital, a life sciences investment fund management firm. From  September 1999 until its merger into Nanogen, Inc. in December 2004, Dr. Gerber was President, Chief Executive Officer and a Director of Epoch Biosciences, Inc., a biomedical company. From April 1998 to July 1999, he was President of diaDexus LLC, a pharmacogenomics company. Previous to his appointment at diaDexus, he was Chief Operating Officer of Onyx Pharmaceuticals. Before joining Onyx in 1995, Dr. Gerber was with Chiron Corporation, a biopharmaceutical, vaccine and blood testing company, where he was President of the Chiron Diagnostics business unit after Chiron's merger with Cetus Corporation in December 1991. He joined Cetus in 1987 as Senior Director of Corporate Ventures and was named Vice President and General Manager of the PCR (Polymerase Chain Reaction) Division in November 1988.Dr. Gerber is Chairman of the Board of Pathway Diagnostics, a private company, and on the board of directors of Nanogen Inc., Radiant Medical Inc., Conatus Pharmaceuticals, Inc., Gentiae Clinical Research, Inc. and Galileo Pharmaceuticals Inc. Dr. Gerber earned his B.S. and M.D. degrees from the University of California, San Francisco School of Medicine.

John W. Larson has served as a member of our Board of Directors since January 1996. Mr. Larson is currently a partner at the law firm of Morgan, Lewis & Bockius LLP. Mr. Larson served as partner at the law firm of Brobeck, Phleger & Harrison LLP (Brobeck) from 1969 until retiring in January 2003, except for the period from July 1971 to September 1973 when he was in government service as Assistant Secretary of the United States Department of the Interior and Counselor to George P. Shultz, Chairman of the Cost of Living Council. From 1988 until March 1996, Mr. Larson was Chief Executive Officer of Brobeck. Mr. Larson serves on the board of the Needham Funds and on the boards of several privately held companies. Mr. Larson holds an L.L.B. and a B.A., with distinction, in economics, from Stanford University.

Margaret A. Liu, M.D. has served as a member of our Board of Directors since March 2005.  Dr. Liu is currently a Visiting Professor at the Karolinska Institutet in Stockholm and until June 2006 was Vice-Chairman of the Board of Transgène in Strasbourg. From 2000 to 2002, Dr. Liu was the Senior Advisor in Vaccinology for the Bill and Melinda Gates Foundation.   From 1997 to 1998 she was Vice President of Vaccines Research and from 1998-2000 was Vice President of Vaccines Research and Gene Therapy at Chiron Corporation. She joined Merck Research Laboratories in 1988 and in 1994 became Senior Director in the Department of Virus and Cell Biology. Dr. Liu serves on the editorial or advisory boards of various scientific journals and has been elected a member of the American Society for Clinical Investigation and a Fellow of the Molecular Medicine Society.  In 2002, Discover magazine named her one of “The 50 Most Important Women Scientists”.  Dr. Liu earned her B.A. in Chemistry, Summa Cum Laude, from Colorado College and an M.D. from Harvard Medical School.  In 2002, she was awarded an honorary Doctorate of Science from Colorado College and has received numerous honorary lectureships.

Steven J. Mento, Ph.D. has served as a member of our Board of Directors since May, 2005. He is President and Chief Executive Officer of Conatus Pharmaceuticals Inc. From 1997 to 2005 he was President and CEO of Idun Pharmaceuticals and prior to that, from 1982 to 1992, Dr. Mento held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January of 1992, he joined Viagene, Inc. as Vice President of Research and Development. Dr. Mento was responsible for directing the company’s transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. In October of 1995, Chiron Corporation acquired Viagene, Inc., and renamed the company Chiron Viagene, Inc. Dr. Mento served as President of Chiron Viagene, Inc. and Vice President of Chiron Corporation until August of 1997. As President, Dr. Mento had overall responsibility for gene therapy research, product development, QA/ QC, GMP manufacturing as well as general administration functions at Chiron Viagene. Dr. Mento holds Bachelor of Arts, Master of Science, and Ph.D. degrees in microbiology from Rutgers University. He did his post-doctoral fellowship in somatic cell genetics at the University of Toronto. Dr. Mento currently serves on the Boards of BIOCOM (Co-Chair of Workforce Development Committee), BIO (Co-Chair of Capital Formation Committee), BIO ECS Governing Body, Grannus BioSciences, UCSD-Division of Biological Sciences Board of Advisors, SDSU BioScience Center Scientific Advisory Board, and UCSD Bannister Family House.He also serves on the BIO Health Section Governing Body Board and the board of Hawaii Biotech.

Michael C. Wood has served as a member of our Board of Directors since our inception. Mr. Wood was founder, CEO and President of LeapFrog Enterprises, Inc. and its predecessor, an educational company from January 1995 through March 2004. Mr. Wood has 15 years of experience in the corporate legal representation of high technology firms and venture capital partnerships. From 1991 through 1994, he was a partner of the emerging technology companies group at Cooley Godward LLP. From 1979 to 1991, Mr. Wood practiced corporate law in the high technology practice of Crosby Heafey Roach & May. Mr. Wood received a J.D. from the Hastings College of Law, an M.B.A. from the University of California, Berkeley and his B.A. in political science from Stanford University .

Scientific Advisory Board

Our Scientific Advisory Board is comprised of experts in molecular biology, structural biology, biophysics, biochemistry, cell biology, and gene expression and includes some of the pioneers in the field of zinc finger DNA binding protein research.

Judith Campisi, Ph.D., is Head, Center for Research and Education in Aging Life Sciences Division of the Berkeley National Laboratory, where she has been conducting aging and cancer research since 1990. From 1984 to 1990, Dr. Campisi held professorships within the Department of Biochemistry at the Boston University School of Medicine. Dr. Campisi received her Ph.D. in biochemistry and a B.A. in chemistry from the State University of New York, Stony Brook.

Barrie Carter, Ph.D. has been the Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation since 1992. Previously, he was at the National Institutes of Health (NIH) for 22 years serving as Chief of the Laboratory of Molecular and Cellular Biology in the National Institute for Diabetes and Digestive and Kidney Diseases from 1982 to 1992. Prior to joining the NIH, he was a post-doctoral fellow at the Imperial Cancer Research Fund Laboratories in London, England. He received his B.Sc. with Honors from the University of Otago, Dunedin, New Zealand and his Ph.D. in the Biochemistry Department of the University of Otago Medical School. Dr. Carter's long-term research interests are in the molecular biology of viruses, development of AAV vectors and gene therapy. Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology. From 1995-2000 Dr. Carter was an Affiliate Professor of Medicine at the University of Washington Medical School. Dr. Carter currently serves as a member of the Advisory Committee to the Director, NIH and is a member of the Board of Directors of the American Society for Gene Therapy.

Michael Gilman, Ph.D. is President and CEO of Stromedix, Inc. and most recently served as Executive Vice President of Research at Biogen Idec, Inc. During his six-year tenure at Biogen Idec, from 1999 to 2005, Dr. Gilman managed discovery research including inflammatory and autoimmune diseases, and cancer. From 1994 to 1999, Dr. Gilman served as Executive Vice President and Chief Scientific Officer of Ariad Pharmaceuticals Inc. where he was responsible for drug discovery activities to develop novel gene- and cell-regulation technologies.
Earlier in his career, Dr. Gilman was a principal investigator at Cold Spring Harbor Laboratory where he ran an active research programs in growth control and cancer, signal transduction and gene transcription and held adjunct academic appointments at SUNY Stony Brook. He earned a Ph.D. in Biochemistry from the University of California, Berkeley, and holds an S.B. in Life Sciences from the Massachusetts Institute of Technology.

Sir Aaron Klug , OM FRS is a member of the MRC Laboratory of Molecular Biology, Cambridge UK. He did much of the founding work on the structure of zinc finger DNA-binding proteins (ZFPs) and their interaction with DNA. He is the recipient of numerous honors and awards including the Nobel Prize for Chemistry. Sir Aaron was director of the MRC Laboratory of Molecular Biology from 1986-1996, and President of the Royal Society. He was a Founder and Director of Gendaq, a company founded in the United KIngdom to commercialize ZFPs and their various applications. Sangamo acquired Gendaq in 2001.

Gabor M. Rubanyi, M.D., Ph.D. is Chief Scientific Officer of Cardium Therapeutics, Inc. Prior to joining Cardium in June 2006, he was Vice President and Head of the Gene Therapy Department at Berlex Biosciences in Richmond, California and Adjunct Professor of Molecular and Cellular Physiology at the University of California at Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex. Formerly, he was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories, Cedar Knolls, New Jersey (1987-1990) and Associate Professor at the Mayo Clinic Medical School, Rochester, Minnesota (1983-1987). The author and co-author of 22 books and over 325 research articles, he serves as an editorial board member for several biomedical journals and is a member of numerous American and international scientific societies. He is the Founder of the biomedical journal Endothelium. His pioneering work on the nature and characterization of endothelium-derived relaxing and contracting factors contributed in a significant way to our present knowledge about endothelial control of vascular function in health and disease.

Kevin Struhl, Ph.D., is the David Wesley Gaiser Professor of Biological Chemistry in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. Struhl has established many of the principles involved in the molecular mechanisms of transcriptional activation and repression in eukaryotic cells including the recruitment of gene-specific and general transcription factors as well as histone deacetylases. Dr. Struhl received his Ph.D. in biochemistry from Stanford University, and S.M. and S.B. degrees from the Massachusetts Institute of Technology.

back to top